|
|
Post by casualinvestor on Mar 19, 2021 10:24:25 GMT -5
As opposed to bond action affecting the stock market, I see it more like there was a broad pump in specific bio/tech/high-sentiment stocks starting in Jan (remember posts abut ST selling sentiment data to hedge funds), then the dump started in mid Feb.
I'm surprised the bubble did not deflate more...but there's still time
|
|
|
|
Post by pat on Mar 21, 2021 6:40:53 GMT -5
Could be. Finance reporters like to throw out that when bond yields rise, so too does the discount rate associated with the future earnings of growth companies. But, along the lines of what you wrote, the euphoria of the herd is probably more responsible for the run up the past 6 months than everybody sitting around running DCF scenarios. SPACs - giving money to someone to invest in an asset to be defined later - will end very well I imagine.
|
|
|
|
Post by jkendra on Mar 23, 2021 13:18:56 GMT -5
More competition - seems like more and more are realizing this is the way to go. respiratherapeutics.com/pipelineProduct Development Respira is developing next-generation cardiopulmonary disease-targeted inhalation products that enhance drug delivery to the lung periphery. Our approach combines Respira’s state-of-the-art AOS™ dry-powder inhaler device and proprietary inhaled drug formulation technologies to enhance dose consistency and drug targeting to the small airways of the lung. RT234-PAH Respira’s lead drug-device product candidate, RT234-PAH, is a first-in-class inhaled therapy intended for as-needed (PRN) use to improve exercise tolerance and provide acute relief from breathlessness and fatigue, the most commonly reported symptoms in pulmonary arterial hypertension (PAH) patients (Group 1 in the World Health Organization’s classification of pulmonary hypertension indications). This contrasts with all current PAH treatments, which are taken according to a chronic treatment regimen and monitored for chronic improvements in outcome measures. RT234 demonstrated excellent safety margins in preclinical testing and was well tolerated in Phase 1 clinical studies, with pharmacokinetic profiles consistent with expectations for a PRN medication. Respira has received FDA Orphan Drug designation for the active ingredient in RT234 (vardenafil, a potent vasodilator that is FDA-approved in an oral form for a non-PAH indication) for the treatment of PAH and is currently in Phase 2 clinical testing for this indication. RT234-ILD PH Leveraging preclinical and Phase 1 studies of RT234-PAH, Respira is developing RT234-ILD PH as a treatment for patients with Interstitial Lung Disease (WHO Group 3.2 Pulmonary Hypertension) to relieve breathlessness and fatigue and improve exercise capacity resulting from elevated pulmonary artery pressures. RT234-ILD PH is Phase 2 clinical trial-ready.  |
|
|
|
Post by porkini on Mar 23, 2021 14:11:29 GMT -5
More competition - seems like more and more are realizing this is the way to go. respiratherapeutics.com/pipelineProduct Development Respira is developing next-generation cardiopulmonary disease-targeted inhalation products that enhance drug delivery to the lung periphery. Our approach combines Respira’s state-of-the-art AOS™ dry-powder inhaler device and proprietary inhaled drug formulation technologies to enhance dose consistency and drug targeting to the small airways of the lung. RT234-PAH Respira’s lead drug-device product candidate, RT234-PAH, is a first-in-class inhaled therapy intended for as-needed (PRN) use to improve exercise tolerance and provide acute relief from breathlessness and fatigue, the most commonly reported symptoms in pulmonary arterial hypertension (PAH) patients (Group 1 in the World Health Organization’s classification of pulmonary hypertension indications). This contrasts with all current PAH treatments, which are taken according to a chronic treatment regimen and monitored for chronic improvements in outcome measures. RT234 demonstrated excellent safety margins in preclinical testing and was well tolerated in Phase 1 clinical studies, with pharmacokinetic profiles consistent with expectations for a PRN medication. Respira has received FDA Orphan Drug designation for the active ingredient in RT234 (vardenafil, a potent vasodilator that is FDA-approved in an oral form for a non-PAH indication) for the treatment of PAH and is currently in Phase 2 clinical testing for this indication. RT234-ILD PH Leveraging preclinical and Phase 1 studies of RT234-PAH, Respira is developing RT234-ILD PH as a treatment for patients with Interstitial Lung Disease (WHO Group 3.2 Pulmonary Hypertension) to relieve breathlessness and fatigue and improve exercise capacity resulting from elevated pulmonary artery pressures. RT234-ILD PH is Phase 2 clinical trial-ready. Maybe, or maybe not so much...? (Source: respiratherapeutics.com/press-releases.php) www.prnewswire.com/news-releases/respira-therapeutics-announces-collaboration-with-united-therapeutics-to-treat-pulmonary-hypertension-300438430.htmland then respiratherapeutics.com/PDFS%20NEWS/2019%201010%20Respira%20Regains%20RT234%20Rights%20from%20UT.pdf |
|
|
|
Post by jkendra on Mar 23, 2021 15:11:34 GMT -5
|
|
|
|
Post by lazyb767 on Mar 23, 2021 15:31:55 GMT -5
Lot of reading between the lines and/or interpretation...
|
|
|
|
Post by helmut8056 on Mar 23, 2021 18:56:30 GMT -5
04//12/2017?? four yrs old!
|
|
|
|
Post by porkini on Mar 23, 2021 20:47:55 GMT -5
|
|
|
|
Post by helmut8056 on Mar 24, 2021 3:48:37 GMT -5
Date of collaboration with UTHR & Respiratheraputics in 2017. History I hope. Thanks for the clarification.
|
|
|
|
Post by letitride on Mar 24, 2021 6:52:13 GMT -5
From Respira website under news releases 10/10/19 Respira Therapeutics Regains North America Rights from United Therapeutics to Phase 2 Inhaled Drug-Device Product, RT234, for Pulmonary Hypertension Indications
|
|
|
|
Post by longliner on Mar 24, 2021 13:54:56 GMT -5
While this is admittedly no fun for longs, this must be hell on the short side. Selling this amount of higher priced shares to bring the price down and not even bring out 5 million in volume? Nice work little fella, if you can breach the 3's I'll humor you and pick up 15,000 more shares. I'll be your huckleberry.  Who trades in.0001 increments for 5 shares on a $3.21 stock? SEC any ideas?  |
|
|
|
Post by mytakeonit on Mar 24, 2021 14:06:42 GMT -5
I'll see your bet and raise you 85,000 shares. Okay mango ... it's your turn now. Hold them or fold them.
But, that's mytakeonit
|
|
|
|
Post by letitride on Mar 24, 2021 15:35:50 GMT -5
Not sure I know what I am talking about but I am thinking the bond issuers are the same ones who ran it up to 6 and are now shorting it back down to where they began buying. From that point they can start covering their short position, and finish with their $5 shares in 2025 if necessary. Is this how an arbitrage works? And if so can we expect to see this return to where my trend line changed in November before we get news?
Inquiring mind wants to know.
|
|
|
|
Post by cretin11 on Mar 24, 2021 18:41:11 GMT -5
While this is admittedly no fun for longs, this must be hell on the short side. Selling this amount of higher priced shares to bring the price down and not even bring out 5 million in volume? Nice work little fella, if you can breach the 3's I'll humor you and pick up 15,000 more shares. I'll be your huckleberry. Who trades in.0001 increments for 5 shares on a $3.21 stock? SEC any ideas? Just a guess here, but chances are pretty good that those who shorted MNKD when it was over $6, or even $5, are not describing this as hell. |
|
|
|
Post by longliner on Mar 24, 2021 20:35:49 GMT -5
While this is admittedly no fun for longs, this must be hell on the short side. Selling this amount of higher priced shares to bring the price down and not even bring out 5 million in volume? Nice work little fella, if you can breach the 3's I'll humor you and pick up 15,000 more shares. I'll be your huckleberry. Who trades in.0001 increments for 5 shares on a $3.21 stock? SEC any ideas? Just a guess here, but chances are pretty good that those who shorted MNKD when it was over $6, or even $5, are not describing this as hell. Without volume....purgatory. |
|
